Cullinan Therapeutics, Inc. - 8-K Filing

Cullinan Therapeutics outlined Q4 2026 milestones for its immunology and oncology pipeline, including data updates on CLN-978, velinotamig, and CLN-049. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $CGEM

Read the full article at SEC EDGAR

More Regulatory news